1. Home
  2. JFU vs LSTA Comparison

JFU vs LSTA Comparison

Compare JFU & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 9F Inc.

JFU

9F Inc.

N/A

Current Price

$2.68

Market Cap

29.9M

Sector

Finance

ML Signal

N/A

Logo Lisata Therapeutics Inc.

LSTA

Lisata Therapeutics Inc.

N/A

Current Price

$1.71

Market Cap

28.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JFU
LSTA
Founded
2006
1980
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Misc Health and Biotechnology Services
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.9M
28.9M
IPO Year
2018
2000

Fundamental Metrics

Financial Performance
Metric
JFU
LSTA
Price
$2.68
$1.71
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$15.00
AVG Volume (30 Days)
8.1K
537.0K
Earning Date
12-09-2022
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
20.42
EPS
N/A
N/A
Revenue
N/A
$35,283,868.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.43
N/A
Revenue Growth
N/A
56.90
52 Week Low
$1.98
$0.99
52 Week High
$9.48
$5.07

Technical Indicators

Market Signals
Indicator
JFU
LSTA
Relative Strength Index (RSI) 51.22 44.49
Support Level $2.06 $1.23
Resistance Level $2.94 $2.08
Average True Range (ATR) 0.25 0.22
MACD -0.02 0.01
Stochastic Oscillator 52.17 36.08

Price Performance

Historical Comparison
JFU
LSTA

About JFU 9F Inc.

9F Inc is a digital technology and wealth management service provider aiming to empower institutional partners with financial technologies as well as attract investors with investment opportunities that come with the vast potential of China's new consumer economy and the appreciation of world-wide assets and access to quality products at a competitive price. The Company's operations are organized into segments, consisting of E-commerce services, technology Empowerment service, and Wealth Management services.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.

Share on Social Networks: